Citius Pharmaceuticals Inc. Common
N/A
USD
N/A
N/A
...
Chart
Financials
Description
CTXR Company Description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
CTXR Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CTXR Smart Score
Score Breakdown
CTXR Company Description
Show More
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of CTXR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CTXR's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on CTXR's company Twitter account
WallStreetBets
Number of mentions of CTXR in WallStreetBets Daily Discussion
CTXR News
Recent insights relating to CTXR
CNBC Recommendations
Recent picks made for CTXR stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CTXR
Corporate Flights
Flights by private jets registered to CTXR
Our Analysis